PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

(2021) Rangarirai Makuku et al.   Journal of Immunology Research

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

(2020) Delvys Rodriguez-Abreu et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies

(2013) Conor Fields et al.   Nature Protocols

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation

(2012) E. E. Weatherill et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY